Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY: ANVS )

2.300 -0.180 (-7.25%)
Streaming Delayed Price Updated: 3:07 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged over 100 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
48 Biggest Movers From Friday
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug... 
Via Benzinga
5 Stocks To Watch For May 24, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Nordson Corporation (NASDAQ: NDSN) to report quarterly earnings at $1.64 per share on revenue of $... 
Via Benzinga
Why Is Annovis Bio's Stock Surging Higher Today?
Annovis Bio Inc (NYSE:ANVS) shares are trading higher b... 
Via Benzinga
Annovis Bio, Inc. Announces Pricing of Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Mid-Afternoon Market Update: Dow Rises 150 Points; VF Corp Shares Fall On Downbeat Earnings
Toward the end of trading Friday, the Dow traded up 0.44% to 34,234 while the NASDAQ fell 0.26% to 13,500.91. The S&P also rose, gaining 0.07% to 4,161.93. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Nasdaq Turns Lower; Annovis Bio Shares Surge
Midway through trading Friday, the Dow traded up 0.71% to 34,327.47 while the NASDAQ fell 0.12% to 13,520.12. The S&P also rose, gaining 0.35% to 4,173.78. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
30 Stocks Moving In Friday's Mid-Day Session
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares jumped 105.4% to $54.23 after the company announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401,... 
Via Benzinga
Annovis Bio Stock Rockets As Alzheimer's Drug Tops Biogen, Cassava Sciences
Annovis Bio said Friday its experimental Alzheimer's and Parkinson's treatment improved cognition in less than a month, leading ANVS stock to soar. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Open Higher; Deere Beats Q2 Estimates
Following the market opening Friday, the Dow traded up 0.84% to 34,370.30 while the NASDAQ rose 0.37% to 13,585.45. The S&P also rose, gaining 0.58% to 4,183.17. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Annovis Bio's Stock Trading Higher As Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement
Annovis Bio Inc (NYSE: ANVS) has announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401, for Alzheimer's disease (AD),... 
Via Benzinga
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Exposures Product Safety
Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 20, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
Berwyn, Pennsylvania--(Newsfile Corp. - May 19, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Exposures Product Safety
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research
Berwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company... 
Via Newsfile
Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - May 13, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Exposures Product Safety
Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Annovis Bio to Ring Closing Bell at the New York Stock Exchange
Berwyn, Pennsylvania--(Newsfile Corp. - May 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
64 Biggest Movers From Yesterday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 82.6% to settle at $6.39 on Monday. Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares surged 53.5% to close at $3.... 
Via Benzinga
Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
Berwyn, Pennsylvania--(Newsfile Corp. - May 6, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
Berwyn, Pennsylvania--(Newsfile Corp. - April 15, 2021) - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's... 
Via Newsfile
Topics Bonds
Exposures Debt Markets
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.